| Project/Area Number |
15591340
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Kagawa University (2004)
Shiga University of Medical Science (2003) |
|---|
Principal Investigator |
KONTANI Keiichi Kagawa Univiesity, Faculty of Medicine, Second Department of Surgery, Associate professor (Lecturer), 医学部附属病院, 講師 (90314153)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
手塚 則明 滋賀医科大学, 医学部, 助手 (40303771)
澤井 聡 滋賀医科大学, 医学部, 助手 (60335172)
藤野 昇三 滋賀医科大学, 医学部, 助教授 (10209075)
西 崇男 滋賀医科大学, 医学部, 助手 (10362378)
白石 昭一郎 滋賀医科大学, 医学部, 助手 (30283568)
|
|---|
| Project Period (FY) |
2003 – 2004
|
| Project Status |
Completed (Fiscal Year 2004)
|
| Budget Amount *help |
¥3,500,000 (Direct Cost: ¥3,500,000)
Fiscal Year 2004: ¥1,300,000 (Direct Cost: ¥1,300,000)
Fiscal Year 2003: ¥2,200,000 (Direct Cost: ¥2,200,000)
|
|---|
| Keywords | dendritic cell / cancer vaccine / tumor antigen / immunotherapy / MUC1 / MUC1ムチン / ワクチン / 癌免疫治療 |
|---|
| Research Abstract |
The use of dendritic cells (DCs) for cancer vaccination is effective in suppressing cancer progression. This is because the DCs play a crucial role in priming tumor-specific immunity efficiently as antigen-presenting cells. In this study, we analyzed the ability of DCs to elicit tumor-specific immunity and clinical effects of DC vaccine immunotherapy targeting MUC1 tumor antigens. DCs from 14 patients with advanced or metastatic breast or lung cancer (9 positive for MUC1 and 5 negative for MUC1) were loaded with MUC1 antigens or tumor lysate and used for therapeutic vaccination. After vaccination, all of the MUC1-positive patients acquired antigen-specific immunity whereas only one case with MUC1-negative cancer showed the specific immunity. Clinically, marked effects such as reduction in tumor sizes or tumor marker levels or disappearance of malignant pleural effusion were observed in 7 of the 9 MUC1-positive cases. However, MUC1-negative patients did not respond to DC vaccines, with the exception of one case with MAGE3-positive lung cancer. Survival of MUC1-positive patients was significantly prolonged in comparison with MUC1-negative patients (mean survival : 16.75 versus 3.80 months, p=.0101). These data suggest that MUC1 is sufficiently immunogenic to elicit strong anti-tumor immunity as a tumor antigen and that DC vaccines targeting MUC1 are useful for immunotherapy of cancer.
|
